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I. INTRODUCTION
Brain metastases constitute the most frequent ma-
lignant disease in the central nervous system (CNS),
outnumbering primary brain tumor cases 10-fold
(1). Up to 20-40% of patients with adult systemic
malignancies will develop brain metastases in the
course of their disease (2). A variety of systemic
malignancies can metastasize to the CNS, although
the majority of the lesions come from lung cancer
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(40-50%) followed by breast cancer (20-30%), mela-
noma (5-10%), lymphoma, and various other pri-
mary sites like the gastrointestinal tract (4-6%) and
prostate (3, 4). Brain metastasis represents a signifi-
cant healthcare problem and has an adverse impact
on patient morbidity and outcome (5). In addition,
tumors in the CNS strongly affect patients’ quality
of life (QOL), impairing sensory and motor neural
functions and inducing headache, nausea, vomiting,
and seizures (6). While conventional treatment regi-
mens provide marginal survival benefits (7), the
prognosis for patients with brain metastases is dis-
mal. With an increasing incidence (8), and a fre-
quent occurrence in patients whose extracranial
cancer has been controlled, brain metastasis is be-
coming a major limiting factor for cancer patients’
QOL and survival.
Lung cancer, including non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC), is the
leading cause of malignancy-related death world-
wide. Lung cancer is the malignancy that most com-
monly gives rise to brain metastases. Approximately
10-25% of lung cancer patients have brain metasta-
ses at initial diagnosis and about 40-50% of them
develop brain metastases during the course of dis-
ease (9). Treatment options are limited and standard
of care is generally whole brain radiation therapy
(WBRT) with corticosteroids to alleviate edema and
overall survival is 3-6 months after diagnosis of
CNS disease. Favorable prognostic factors that af-
fect survival include Karnofsky’s performance status,
patient age (65 years), control of primary tumor,
and absence of extracranial metastatic disease (10).
To overcome lung cancer brain metastases, an un-
derstanding of the molecular biology of brain metas-
tasis is crucial. The current review gives a broad
overview about the accumulating recent knowledge
of lung cancer brain metastasis and the latest devel-
opments in the field.
II. BIOLOGY OF BRAIN METASTASIS
Similar to the metastatic process in other organs,
brain metastasis formation is a highly selective,
multi-step process, involving complex interactions
between tumor and host cells, which is clearly ex-
plained by the “seed-and-soil” hypothesis (11, 12).
The brain is considered as a “sanctuary” site
for metastatic cancer cells because many of the
therapeutic agents can not cross the blood-brain
barrier (BBB) (13). The BBB is a network com-
posed of both endothelial cells and supporting com-
ponents that protects the CNS microenvironment.
In contrast to the periphery, the endothelium of
brain micro-vessels is characterized by continuous
tight junctions (TJs), decreased pinocytosis activity,
very low pinocytic activity, and overexpressed efflux
pumps (14) (Figure 1). With the reinforcement of
the surrounding extracellular matrix (ECM), basal
membrane, pericytes, and the end-feet of astrocytes,
the BBB effectively prevents the free exchange of
substances between the blood and the interstitial
fluid of the brain (15). Therefore, the brain forms
a special challenge for tumor cells because of BBB
and all other steps have to be successfully completed
Figure 1. Schematic comparison of a brain capillary with a capillary in the periphery. Schematic structure of the blood-brain barrier.
Cerebral endothelial cells, coming in contact with pericytes and astrocytes, form the morphological basis of the blood-brain barrier.
Endothelial cells are interconnected by a continuous line of tight junctions (Cited from reference number 14 and revised).
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for tumor cells to invade through BBB and sur-
vive.
When metastatic cancer cells enter the brain
circulation, they might arrest in sites of slow flow
within the capillary bed at vascular branch points.
Then, interactions between cancer cells and brain
endothelial cells or transendothelial migration are
mediated by interaction of tumor cell-surface recep-
tors and endothelial cell adhesion molecules (16).
After overcoming the BBB, tumor cells are con-
fronted with components of the local microenviron-
ment including the extracellular matrix (ECM), resi-
dent brain parenchymal cells (astrocytes, microglia),
and paracrine signaling molecules including cy-
tokines and growth factors (16). Survival and suc-
cessful tumor growth require adaption to and inter-
action with these factors. The brain also establishes
an adequate blood supply via angiogenesis, angio-
ectasia, vasculogenesis, vasculogenic mimicry, mak-
ing brain metastases grow and proliferate better
(17). During the above process, functional signifi-
cance of gene expressions, changes in brain vas-
culature, abnormal secretion of soluble factors and
activation of autocrine/paracrine signaling contribute
to the brain metastasis development.
III. MOLECULAR PATHWAYS MEDIATING
LUNG CANCER BRAIN METASTASIS
1. Gene expression analyses
In order to identify pathways specific to the de-
velopment of brain metastasis and novel molecular
targets/translational leads, several groups have un-
dertaken gene expression studies in animal models
and human tissue cohorts.
Kikuchi et al. compared gene expression of pri-
mary lung adenocarcinoma with brain metastases
originating from these tumors. Of 23,040 genes
tested, 244 showed a different expression level, in-
cluding genes coding for plasma membrane pro-
teins, cellular antigens and cytoskeletal proteins,
which may modulate cell-cell interactions (18).
Brain metastases of lung adenocarcinoma were
evaluated in another study as well, by comparing the
gene expression profile of metastatic brain tumors
originating from lung adenocarcinoma with that of
healthy lung. Zohrabian et al. have found 1,561 dif-
ferently expressed genes by using cDNA microar-
ray. The overexpression of genes associated with
invasion and metastasis, adhesion, angiogenesis and
cell migration was validated by real-time PCR (19).
In a cohort of primary tumors from lung cancer
patients who developed brain metastases, Grinberg-
Rashi et al. found the expression levels of three
genes, CDH2, KIFC1, and FALZ, was highly pre-
dictive of brain metastases (20). N-cadherin, which
is coded by CDH2 gene, is involved in multiple proc-
esses including inducing invasion, migration, pro-
moting survival of cancer cells, regulating adhesion
and neurite outgrowth (21). Clinically, N-cadherin
overexpression has been shown to be associated
with decreased survival in poorly differentiated
SCLCs (22).
DCUN1D1, a squamous cell carcinoma-related
oncogene, is associated with tumor progression
and poor outcomes in NSCLC. Recently, the over-
expression of DCUN1D1 has been found to be use-
ful in identifying patients who are at higher risk
for brain metastases. Yoo et al. showed that 14 of
16 DCUN1D1-positive NSCLC patients (87.5%) re-
sulted in brain metastases (23).
However, as previously reported in other primary
and metastatic clinical or experimental tumors (24-
26), the genetic heterogeneity would limit the trans-
lation of the gene profiles into the clinical trials.
2. Cell surface molecules
1) Integrins
Integrins are a family of cell surface receptors
that mediate cell adhesion and signal transduction.
Integrins interact with ECM components such as
collagen, laminin, and fibronectin and play crucial
roles in cell migration. Integrins can also activate
signaling cascades to mediate cell survival (27). The
expression of integrin α3β1 has been associated
with lung cancer brain metastasis. Compared with
their parental cell line and bone-metastasizing coun-
terparts, tumor cells that preferably metastasize
to the brain highly expressed α3β1 integrin (28).
Moreover, inhibiting α3β1 integrin function de-
creased brain metastases formation in nude mice
(28). It has been posited that the interaction of the
α3β1 integrin with laminin, which promotes tumor
cell migration and invasion, may be critical to this
effect (28).
2) Immunoglobulin superfamily of cell adhesion mole-
cules
Endothelial cells express several adhesion mole-
cules belonging to the immunoglobulin superfamily,
including members of the intercellular adhesion
molecules (ICAMs), vascular-cell adhesion molecule
(VCAM) and platelet-endothelial-cell adhesion mole-
cule (PECAM) (29). These are essential in immune
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response and inflammation, but some of them were
also shown to be involved in the interaction of vas-
cular endothelial and tumor cells and formation of
metastases. Recently, ICAM-1 and VCAM-1 were
shown to play a crucial role in polychlorinated bi-
phenyl-mediated enhancement of brain metastasis
formation of lung carcinoma cells (30).
3) Cadherins
Cadherin dysfunction is involved in tumor pro-
gression and metastasis formation. Loss of expres-
sion of E-cadherin induces epithelial-mesenchymal
transition (EMT) in carcinoma cells, which initi-
ates an increase in cell motility and metastasis for-
mation. In metastatic lesions, a re-expression of
E-cadherin has been observed, which plays an im-
portant role in the proliferation of tumor cells at the
metastatic site. Correspondingly, metastatic brain
tumors were shown to express high levels of E-
cadherin (31), while low expression of E-cadherin
in primary NSCLC was shown to correlate with in-
creased risk for the development of brain metastasis
(32). In addition, the expression level of N-cadherin
was observed to be highly predictive of brain me-
tastasis formation in NSCLC (20).
3. Soluble factors
1) Vascular endothelial growth factor (VEGF)
Angiogenesis is an important aspect of tumor
metastasis. Recent studies have examined the roles
of VEGF, which influences both angiogenesis and
blood vessel permeability. VEGF signaling and func-
tion in brain metastasis has also been extensively
characterized in preclinical models. Measurement
of VEGF levels in the culturing media of cells grow-
ing in vitro has shown that VEGF is secreted by
tumor cells with high brain metastatic activity (33).
Increased VEGF secretion has also been detected
in brain metastasis xenografts in nude mouse mod-
els (33). Antisense VEGF transfectants of PC14-PE6
lung adenocarcinoma cells exhibited a decreased
incidence of experimental brain metastases, suggest-
ing that VEGF is necessary for brain tumor initiation
and growth (33). Jubb et al. compared VEGF ex-
pression, proliferation, microvessel density, vascular
pattern and vascular maturity in matched primary
NSCLC and brain metastases (34). They found that
brain metastases are characterized by a significantly
higher proliferation rate and vascular maturity than
their matched primaries. These findings are impor-
tant because if the vasculature of brain metastasis is
mature, then patients with cerebral secondaries may
be less likely to respond to anti-VEGF treatment,
even though patients with primary NSCLC might
benefit from such therapy (34).
2) Placental growth factor (PlGF)
Li et al. (35) recently found PlGF, a member of
VEGF subfamily, may be associated with SCLC
brain metastasis. PlGF in the serum of SCLC pa-
tients with brain metastases was significantly higher
than that without brain metastases and normal speci-
mens. In addition, SCLC cell-derived PlGF activates
the VEGFR1/Rho/ERK signaling pathway in cere-
bral endothelial cells, resulting in the disassembly
of TJs and promoting transendothelial migration
(35). Moreover, the down-regulation of PlGF sup-
pressed SCLC cell metastasis to the brain in an ex-
perimental brain metastasis model.
3) Chemokines
Chemokines play an important role in cell migra-
tion, invasion and tumor angiogenesis (36). Emerg-
ing data support the putative involvement of the
CXCR4/CXCL12 signaling axis in NSCLC brain me-
tastasis (37). High CXCL12 expression within sites
of lung cancer metastasis has been demonstrated
in mouse xenograft studies (38). Hartmann et al.
showed that the CXCR4 chemokine receptor closely
co-operates with integrins to promote adhesion and
chemoresistance of SCLC cells (39). Overexpres-
sion of CXCR4 and CXCL12 has been described in
histolopathological specimens of brain metastases
and correlated with brain-specific metastasis in a
cohort of NSCLC patients (40). In a recent study,
Paratore et al. (41) have investigated the expression
of CXCR4/CXCL12 in primary NSCLC specimens of
patients with and without brain metastases. CXCL12
and CXCR4 immunoreactivities in metastatic NSCLC
samples were significantly higher than that in paired
non-metastatic NSCLC.
4. Proteases
1) Matrix metalloproteinases (MMPs)
Different proteolytic enzymes have been impli-
cated in brain metastasis formation and migration of
tumor cells through BBB endothelial cells. MMPs
might have special importance in the process of
transendothelial migration of tumor cells through
the BBB, because TJ proteins can be targets of
MMP degradation. MMP-induced disruption of TJs
was shown to promote invasion of tumor cells into
the CNS (42). MMP-9 was reported to be overex-
pressed by brain metastatic lung adenocarcinoma
cells (43).
2) A disintegrin and metalloprotease 9 (ADAM9)
ADAM-9 is a membrane-tethered protease and
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belongs to a member of the “a disintegrin and met-
alloprotease” family. ADAM9 is overexpressed in
brain metastatic lung cancer cells. Shintani et al.
found that the expression of ADAM9 up-regulated
integrin α3β1 and facilitated brain metastasis for-
mation (44).
5. Driver mutations
1) Epidermal growth factor receptor (EGFR) mutations
It is found that driver mutations in NSCLC, at
least in part, would be associated with brain metas-
tases. In East Asian patients, Matsumoto et al. (45)
and Gow et al. (46) have found EGFR mutations in
63 and 44% of brain metastases, respectively. This
prevalence is similar to that reported in primary tu-
mors of the same population, varying from 30 to 50%
(47, 48). Among the 110 patients enrolled, Li et al.
found the frequencies of EGFR mutations were 64%
and 31% in the patients with and without brain me-
tastases, respectively (49). Eichler et al. showed that
the numbers of brain metastases were significantly
higher in patients with EGFR-mutated NSCLC com-
pared to those with wild-type (50). Sekine et al.
demonstrated that NSCLC patients with the exon
19 deletions had more multiple and smaller brain
metastases with smaller peritumoral brain edema
than those without any mutations (51). Moreover,
Heron et al. (52) reported that tumors with exon 19
deletions showed a higher incidence of CNS involve-
ment as compared with tumors bearing a L858R
mutation (21% vs. 3%). While published data are
limited to draw any definite conclusions, brain me-
tastases would be more frequent in NSCLC patients
with EGFR mutations.
2) Anaplastic lymphoma kinase (ALK) translocations
More recently, ALK translocations have been
found to be another ‘‘druggable’’ alteration besides
activating EGFR mutations in NSCLC (53). ALK
translocations appear to be constant between pri-
mary tumors and brain metastases (54), and ALK-
positive tumors may predispose to brain metastasis
formation (55). In contrast, Doebele et al. found pa-
tients with ALK translocations were predisposed
to liver, but not adrenal, bone, or brain metastases,
compared to ALK-negative cohort (56). Further
studies should be required to clarify the significance
of ALK translocations in NSCLC patients with brain
metastases.
6. Growth factors and signaling pathways
1) Wnt signaling
The activation of canonical Wnt/TCF pathway has
also been identified as playing a role in lung cancer
spread to the brain. Treatment of a brain-seeking
lung cancer cell line H2030-BrM3 with Wnt3a sig-
nificantly increased the expressions of the WNT/
TCF target genes, LEF1 and HOXB9. Confirming
that LEF1 and HOXB9 are involved in metastasis,
overexpression of the two genes led to an increase
in brain metastases whereas knockdown of each
gene decreased metastatic incidence (57). Support-
ing the hypothesis that TCF4 may play an important
role in lung cancer development, Xu et al. found in-
creased TCF4 overexpression in lung cancer pa-
tients with advanced stages (stage III-IV) compared
with early stages (stage I-II) (58). Furthermore, ex-
pression of Wnt3a in a four-gene signature pre-
dicted increased mortality rates in lung cancer pa-
tients (59).
2) Rho/Rho kinase (ROCK) signaling
During invasion of tissues and migration through
vessel walls and ECM components, metastasizing
tumor cells require increased motility, which is de-
pendent on the remodeling of the cytoskeleton.
Rho/ROCK pathways had been proposed to be in-
volved in the regulation of paracellular permeability
and junctional dynamics in endothelial cells (60).
While little is known about the behavior of tumor
cells during transmigration through the BBB, it has
been shown that inhibition of ROCK decreases the
migration of SCLC cells through the brain endo-
thelium (61).
3) Hepatocyte growth factor (HGF)/Met signaling
The receptor tyrosine kinase Met and its ligand
HGF promoted metastatic spread to the lung, liver
and brain in an experimental model using the NCI-
H460 lung cancer cell line (62). A study of matched
lung cancer brain metastases and primary tumors
from the same patients identified increased expres-
sion of total and phosphorylated c-Met in the brain
metastases. The expression and activation of c-Met
in the primary lung tumors also correlated with the
development of brain metastases (63).
4) Phosphoinositide 3-kinase (PI3K)-Akt signaling
The PI3K-Akt pathway is a crucial regulator of
cell survival and proliferation, and increased PI3K
activity has been reported in several cancer types.
Recently, a PI3K inhibitor was found to effectively
control metastatic growth of HER2-positive breast
cancer cells in multiple organs, including brain me-
tastases (64). However, inhibition of PI3K had no
effect on the transmigration of SCLC cells through
brain endothelial cells (61).
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5) Endothelin (ET)/ET receptor signaling
The binding of ET to the ET receptors exerts
pleiotropic biological effects that influence cell sur-
vival, proliferation, invasion, metastasis, as well as
angiogenesis (65). In a preclinical model of sponta-
neous melanoma brain metastasis, Cruz-Muñoz et
al. have identified the alterations in the expression
of ET receptor as a potential factor that influences
brain metastatic potential. Induced overexpression
of this gene mediated enhanced overall metastatic
disease, and resulted in an increased incidence of
spontaneous brain metastases (66). We recently
demonstrated that the blockade of ET receptor sig-
nificantly inhibited experimental brain metastases
of human NSCLC cells (67).
7. MicroRNA (miRNA)
Mounting evidence indicates that miRNA may be
key players in the regulation of tumor cell invasion
and metastasis. Chen et al. (68) found miR-378 was
significantly differentially expressed in the matched
NSCLC surgical specimens from 8 patients with
brain metastases and 21 without brain metastases.
Arora et al. (69) reported that miR-328 had a role
in conferring migratory potential to NSCLC cells,
which might be incorporated into clinical treatment
decision making to stratify NSCLC patients at higher
risk for brain metastases.
8. Single nucleotide polymorphisms (SNPs)
Studying multiple SNPs in signaling pathways
may be useful for pinpointing the genes and poly-
morphisms involved in conferring risk of brain me-
tastases (70). Multivariate analyses of 33 SNPs from
13 genes in the transforming growth factor-β (TGF-
β) signaling pathway have revealed that the GG
genotype of SMAD6 : rs12913975 and TT genotype
of INHBC : rs4760259 were associated with a sig-
nificantly higher incidence of brain metastasis in
patients with NSCLC at 24 months follow-up, com-
pared with the GA or CT/CC genotypes, respec-
tively (71). In melanoma, TGF-β2 was reported to
be crucial, since its expression is indispensable for




Tumor markers may be helpful in the prediction
of brain metastases. Among them, carcinoembronic
antigen (CEA) is the most widely studied. Lee et al.
found that the pretreatment serum CEA level was
significantly correlated with brain metastases in 227
advanced NSCLC patients (73). Arrieta et al. also
reported that high serum CEA level at diagnosis is
an independent prognostic factor of CNS metastasis
development and survival in patients with advanced
NSCLC (74). They considered that surface expres-
sion of CEA in tumor cells could be a mechanism of
invasion to CNS through immunoglobulin-related
transport in BBB.
Pro-gastrin-releasing peptide (ProGRP) is a
widely used tumor marker for the screening of
SCLC. Yonemori et al. retrospectively analyzed the
characteristics of the first failure event due to brain
metastasis in SCLC patients treated with prophylactic
cranial irradiation (PCI). Elevation of ProGRP level
before PCI was found to be a significant predictive
factor for brain metastasis on multivariate analysis
(75).
2) Indicators of CNS injury in the blood
Elevated levels of certain proteins or neurotrans-
mitters in the blood may be indicators of CNS dam-
age caused by invasion of brain metastases (70).
S100β is a nervous system specific cytoplasmic pro-
tein found in astrocytes and is released into serum
when the BBB is breached (76). However, a con-
founding factor was the presence of BBB changes
due to cerebrovascular disease. Therefore, patients
who are found to have evidence of chronic cere-
brovascular disease will likely receive no further
benefit from routine screening of their serum S100β
level. More recently, proapolipoprotein A1, the pre-
cursor of the cholesterol-binding protein apolipo-
protein A1, was reported to be significantly in-
creased in patients with CNS disease compared
with those affected only by vascular diseases (77).
10. Role of astrocytes in brain metastasis formation
Astrocytes have an indispensable role in the main-
tenance of BBB properties of cerebral endothelial
cells. Therefore, they support endothelial cells in
impeding tumor cells from penetrating into the
brain. On the other hand, astrocytes have a pro-
tective role for brain metastases. Reactive astrocytes
induce the protection of tumor cells from chemo-
therapy through sequestration of calcium from the
cytoplasm of tumor cells and by up-regulating sur-
vival genes in tumor cells (78, 79). Moreover, astro-
cytes secrete soluble factors that stimulate the pro-
liferation of tumor cells in the brain microenviron-
ment. In addition, astrocytes were shown to induce
proliferation of lung and breast cancer cells by pro-
ducing interleukin (IL)-1β, tumor necrosis factor-α
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(TNF-α) and/or IL-6 (80, 81). These proinflamma-
tory cytokines secreted by astrocytes might not only
induce proliferation of tumor cells, but also support
the transendothelial migration and formation of new
metastatic colonies in the brain.
IV. TARGETED THERAPIES FOR LUNG
CANCER BRAIN METASTASIS
In the study by Kienast et al. , the VEGF-A inhibi-
tor bevacizumab blocked angiogenesis and resulted
in dormancy of brain metastasis derived from lung
cancer cells (82), indicating that anti-angiogenic
agents might be promising to inhibit brain metas-
tasis. In early clinical studies, hemorrhagic episodes
were reported after treatment with bevacizumab in
patients with metastatic spread, including brain me-
tastasis (83). In consequence, guidelines prohibited
the use of bevacizumab in this cohort and patients
with brain metastasis have been excluded from par-
ticipating in clinical trials that investigated anti-
angiogenic drugs (84, 85). However, recent large
meta-analyses performed in over 10,000 patients that
received anti-angiogenic agents revealed that these
drugs do not increase the risk of intracranial bleed-
ing compared to the untreated population with brain
metastasis (0.8-3.3% bleeding risk) (85). These re-
ports have prompted to change the guidelines and
allow administration of bevacizumab in patients with
brain metastasis from non-squamous NSCLC (84).
Based on the new guidelines, the decision to use
anti-angiogenics in this patient cohort should be
made upon careful assessment of the potential bene-
fits and risks for individual patients (85).
The EGFR tyrosine kinase inhibitors (EGFR-
TKIs), gefitinib and erlotinib, have been tested in
patients with NSCLC and brain metastasis (50, 86,
87). Similar to primary tumors, the response of brain
metastasis to EGFR inhibitors is better in patients
with activating EGFR mutations while the activity
of these drugs in individuals with wild-type EGFR
metastatic disease is very modest (50, 86, 87). In-
terestingly, the response of chemotherapy-naïve,
never-smoker patients with brain metastases after
treatment with erlotinib and gefitinib was 74%, and
maybe inhibition of EGFR in this patient subgroup
is more effective compared to other cohorts (88).
The BBB penetrability of erlotinib might be better
than gefitinib as small but measurable penetration
of erlotinib into cerebrospinal fluid (CSF) has been
documented (89). Notably, the incidence of CNS
progression after treatment with gefitinib or erlotinib
was lower in NSCLC patients with EGFR mutations
compared to patients with wild-type EGFR and
therefore these targeted agents might also have a
value as prophylactic agents (52). Furthermore, the
resistance EGFR mutation T790M occurs also in
CNS metastasis. Whether afatinib, a second gen-
eration EGFR inhibitor that inhibits T790M also
has activity in CNS metastasis with this mutation
remains to be determined. In one report, encour-
agingly, dose escalation of afatinib resulted in re-
mission of a brain metastasis (90). The question
whether erlotinib or gefitinib should be combined
with other WBRT or stereotactic radiosurgery is
subject of current studies.
Activation of ALK oncogene leads to fusion of
ALK and the echinoderm microtubule-associated
protein-like 4 (EML4) that is encountered in ap-
proximately 4% of patients with NSCLC. The tar-
geted agent crizotinib inhibits this oncogenic fusion
and can lead to effective local tumor control (91). In
a recent case report of a patient with EML4-ALK
fusion, though, brain metastasis developed despite
control of extracerebral metastases (92). Very low
levels of crizotinib were detected in plasma and CSF
of the patient, suggesting insufficient BBB penetra-
bility for this agent (92). However, another recent
case report demonstrated a twelve-month progres-
sion-free survival after treatment with crizotinib in
a patient with lung adenocarcinoma with EML4-
ALK fusion that developed metachronous miliary
lung metastases and brain metastasis (93).
V. CONCLUSION
Brain metastasis has become an increasingly chal-
lenging clinical problem, largely due to the recently
improved clinical control of systemic metastatic dis-
eases. While the biology of brain metastasis is still
poorly understood, it is encouraging to see more ef-
forts are beginning to be directed toward the study
of brain metastasis.
The biomarkers mentioned in this review would
be promising tools for the prediction of brain metas-
tases. However, currently none of them can predict
occurrence of brain metastases alone and much
challenge remain for their translation into practice.
In this article, the mechanistic basis of lung cancer
metastasis to the brain is described (Table 1). The
better understanding of molecular biology of lung
cancer brain metastasis, including heterogeneous
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genetic profiles, is essential to find appropriate tar-
gets of prevention of brain metastasis formation. In
addition, prospective randomized clinical studies are
needed to further assess the utility of these biologi-
cal markers.
It is indisputable that the microenvironment cells
Table 1. Risk factors for the development of lung cancer brain metastasis.
Risk factors Authors Reference No.
Genes
high CDH2 expression Grinberg-Rashi H et al. 20
high KIFC1 expression Grinberg-Rashi H et al. 20
low FALZ gene expression Grinberg-Rashi H et al. 20
high DCUN1D1 expression Yoo et al. 23
Cell surface molecules
high α3β1 integrin expression Yoshimasu T et al. 28
high ICAM-1 expression Sipos E et al. 30
high VCAM-1 expression Sipos E et al. 30
low E-cadherin expression Yoo JY et al. 32
Saad AG et al. 9
high N-cadherin expression Grinberg-Rashi H et al. 20
Soluble factors
high VEGF expression Saad AG et al. 9
Yano S et al. 33
Hu L et al. 43
Kienast Y et al. 82
high PlGF expression Li B et al. 35
high CXCR4 expression Salmaggi A et al. 40
Paratore S et al. 41
high CXCL12 expression Salmaggi A et al. 40
Paratore S et al. 41
Proteases
high MMP-9 expression Hu L et al. 43
high ADAM9 expression Shintani Y et al. 44
Driver mutations
EGFR mutation Li Z et al. 49
Eichler AF et al. 50
ALK translocation Yang P et al. 55
Signaling pathways
activation of WNT/TCF signaling Nguyen DX et al. 57
activation of Rho/ROCK signaling Li B et al. 61
activation of HGF/Met signaling Navab R et al. 62
Benedettini E et al. 63
Circulating markers
CEA elavation Lee DS et al. 73
Arrieta O et al. 74
ProGRP elavation Yonemori K et al. 75
Others
high Amphiregulin expression Sun M et al.
low Caspase-3 expression Saad AG et al.
high Caveolin-1 expression Cassoni P et al.
low CD44 expression Kergi HA et al.
high EGF expression Sun M et al.
high ERCC1 expression Gomez-Roca C et al.
high IGF-1 expression Hwang CC et al.
high Ki-67 levels Saad AG et al.
low Neuregulin1 expression Sun M et al.
inactivating mutation of PTEN Hahn M et al.
high S100A7 expression Zhang H et al.
high phosphorylated Her3 expression Sun M et al.
high phospho-S6 expression McDonald JM et al.
low TGF-α expression Sun M et al.
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in the tumor stroma contribute significantly to the
outgrowth of cancer cells both at the primary site
and in distant metastatic organs. The occurrence of
brain metastasis reflects the culmination of such
tumor-microenvironment interactions. Particularly,
the specialized physiology of the brain not only con-
tributes to the colonization of metastatic tumor le-
sions but also significantly affects the efficacy and
outcome of therapeutic interventions. Future clinical
interventions to treat patients with brain metastasis
must take into consideration the impact of these im-
portant microenvironmental determinants.
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